ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- Engineered Dendritic Cells Harness Tumor EVs to Boost Cancer Immunotherapy
- Top FDA Gene and Cell Therapy News: 2025 Year-End Recap
- Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy
- The 98% mystery: Scientists just cracked the code on “junk DNA” linked to Alzheimer’s
- New method preserves iPS cells for regenerative medicine
- MIT Scientists Have Discovered a Way To Rejuvenate the Immune System
